Study on the activation rate of the pancreatic succus and on the proteolytic activity, as a function of the dose of kinase

被引：0
|
作者：
Guillaumie, M
机构：
来源：
COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES | 1934年 / 116卷
关键词：
D O I：
暂无
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：873 / 876
页数：4
相关论文
共 50 条
  • [31] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    Feliu, J.
    Borrega, P.
    Leon, A.
    Lopez-Gomez, L.
    Lopez, M.
    Castro, J.
    Belda-Iniesta, C.
    Barriuso, J.
    Martinez, V.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 215 - 221
  • [32] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic carcinoma
    Espinosa, E.
    Feliu, J.
    de Castro, J.
    Belda, C.
    Casado, E.
    Herrero, A.
    Sereno, M.
    Pinto, A.
    Gomez, C.
    Baron, M. Gonzalez
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] A gain of function mutation in the activation loop of platelet-derived growth factor β-receptor deregulates its kinase activity
    Chiara, F
    Goumans, MJ
    Forsberg, H
    Ahgrén, A
    Rasola, A
    Aspenström, P
    Wernstedt, C
    Hellberg, C
    Heldin, CH
    Heuchel, R
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (41) : 42516 - 42527
  • [34] The c-Jun kinase signaling cascade promotes glial engulfment activity through activation of draper and phagocytic function
    MacDonald, J. M.
    Doherty, J.
    Hackett, R.
    Freeman, M. R.
    CELL DEATH AND DIFFERENTIATION, 2013, 20 (09): : 1140 - 1148
  • [35] The c-Jun kinase signaling cascade promotes glial engulfment activity through activation of draper and phagocytic function
    J M MacDonald
    J Doherty
    R Hackett
    M R Freeman
    Cell Death & Differentiation, 2013, 20 : 1140 - 1148
  • [36] A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer.
    Kobrossy, B
    El-Rayes, BF
    Shields, AF
    Vaishampayan, U
    Heilbrun, L
    Zalupski, MM
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 343S - 343S
  • [37] A phase II study of fixed-dose rate (FDR) genicitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa).
    Ko, AH
    Dito, E
    Schillinger, B
    Venook, AP
    Bergsland, EK
    Allen, J
    Tempero, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 340S - 340S
  • [38] DOSE-RATE CONTROL IN TOMOGRAPHY - STUDY OF IMAGE QUALITY FROM A TRANSFER-FUNCTION STANDPOINT
    HARDING, G
    RADIOLOGIA DIAGNOSTICA, 1979, 20 (04) : 581 - 586
  • [39] Plasma thymidine kinase activity as a prognostic biomarker in pancreatic ductal adenocarcinoma: a single-center prospective study
    Asplund, Ebba
    Bergqvist, Mattias
    Krook, Maura
    Lohr, J. -Matthias
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (09) : 1044 - 1048
  • [40] Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: A phase II study
    Kim, Hawk
    Park, Jae-Hoo
    Shin, Su Jin
    Kim, Mee-Ja
    Bang, Sung-Jo
    Park, Neung Hwa
    Nah, Yang Won
    Nam, Chang Woo
    Joo, Kwang Ro
    Min, Young Joo
    CHEMOTHERAPY, 2008, 54 (01) : 54 - 62
12345